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ABSTRACT 
 
Bradykinin, a pro-inflammatory molecule, and its related peptides have been studied for their 
effects on acute reactions in upper and lower airways, where they can be synthesised and 
metabolized after exposure to different stimuli including allergens and viral infection. Bradykinin 
B1 and B2 receptors are constitutively expressed in the airways on several residential and/or immune 
cells. Their expression can also be induced by inflammatory mediators, usually associated with 
eosinophil and neutrophil recruitment, such as IL-4, IL-13, TNF-, IL-6 and IL-8,  via intracellular 
MAPK and NF-κB signalling. In turn,  the latters up-regulate both bradykinin receptors. Bradykinin 
activates epithelial/endothelial and immune cells, neurons and mesenchymal cells (such as 
fibroblasts, myofibroblasts and smooth muscle cells), which are implicated in the development of 
airway chronic inflammation, responsiveness and remodelling (a major feature of severe asthma). 
This review highlights the role of bradykinin and its receptors in respect to chronic inflammatory 
response involving eosinophils/neutrophils and to vascular/matrix-related airway remodelling in 
asthmatic airways. This scenario is especially important for understanding the mechanisms involved 
in the pathogenesis of eosinophilic and/or neutrophilic asthma and hence their therapeutic approach.  
 
 
KEY WORDS: bradykinin, bradykinin receptors, asthma, severe asthma, airway inflammation, 
airway remodelling.  
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1. Introduction  
Bradykinin is a key regulator of vascular tone, acute inflammation, pain and cancer (Kaplan et al., 
2002; Leeb-Lundberg et al., 2005; Kashuba et al., 2013). In asthma, bradykinin induces acute 
inflammatory responses in the airways, including plasma protein extravasation and smooth muscle 
contraction leading in turn to airway obstruction (Abraham et al., 2006). Acute anaphylactic 
response in allergic asthma is characterised by mast cells-derived mediators of inflammation and 
kinins formation with subsequent involvement of tachykinins (Geppetti et al., 1995). Furthermore, 
bradykinin is an indirect stimulus of bronchial hyperresponsiveness (Van Schoor et al., 2000) and a 
negative modulator of excessive bronchoconstriction, via the release of epithelium-derived 
bronchoprotective factors in asthma (Figini et al., 1996; Ricciardolo et al., 1996).  
The bradykinin pathway is also involved in several processes related to asthma pathophysiology, 
such as the recruitment of eosinophils (Gurusamy et al., 2016) and neutrophils (Sodhi et al.,  2017), 
the synthesis of “nitrosative stress” products  (MacPherson et al., 2001; Fitzpatrick et al., 2009; 
Ricciardolo et al. 2006; Ricciardolo et al., 2012) and vascular/matrix-related remodelling 
(Ricciardolo et al., 2013). This review is focused on recent discoveries regarding the capability of 
bradykinin to amplify inflammatory responses and to influence cellular/molecular pathways 
involved in airway remodelling in asthma.  
 
2. Synthesis and physiological effects of bradykinin  
Bradykinin is produced by enzymatic cleavage of high and low molecular weight kininogens 
located, respectively in plasma and tissues. Specifically, plasma kallikrein cleaves high molecular 
weight kininogens while tissue kallikrein acts on low molecular weight kininogens. Both enzimes  
produce two low-molecular-weight vasoactive peptides: the nonapeptide bradykinin (arg-pro-pro-
gly-phe-ser-pro-phe-arg), and the 10-amino-acid peptide lysyl-bradykinin or kallidin (excellent 
reviews exist on kinins formation (Kaplan et al., 2002; Kaplan and Ghebrehiwet, 2010)). 
Bradykinin and kallidin are collectively referred to as kinins. 
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Kinins participate in inflammatory processes by their ability to activate structural and inflammatory 
cells.  Bradykinin has been shown to induce vasodilatation (Yamawaki et al., 1994) and vascular 
permeability (Ricciardolo et al., 1994a); it mediates the recruitment of inflammatory cells (Sato et 
al., 2000; Perron et al. 1999; Duchene et al. 2007), the production of nitric oxide (Ricciardolo et al., 
2000) and the release of prostanoids (Li et al., 1998), tachykinins (Geppetti et al., 1995) and 
cytokines/chemokines (Koyama et al., 2000). In addition, bradykinin induces spasm of airway 
smooth muscle (Figini et al., 1996) with subsequent increase of airway resistance (Ricciardolo et 
al., 1994b). As illustrated in Fig. 1, bradykinin can also provoke stimulation of sensory neurons 
resulting in chronic hyperalgesia (Schuelert et al., 2015), alter the ion secretion by epithelial cells 
(Cozens et al.,1994) and modulate cell migration and tissue injury (Abraham et al., 2006) (Fig. 1).  
Bradykinin and kallidin display their biological effects upon binding and activation of their specific 
receptors B1 and B2. Bradykinin B1 receptor usually binds [des-Arg
9]-bradykinin and [lys-des-
Arg9]-bradykinin, the latter is considered more selective (Leeb-Lundberg, 2005). Bradykinin B1 
receptor is constitutively expressed in inflammatory, but not in residential, cells and it is regularly 
induced as a result of inflammation (Christiansen et al., 2002) in the presence of cytokines such as 
interleukin (IL)-1 and tumor necrosis factor (TNF)- (Gurusamy et al., 2016). Bradykinin B2 
receptors show high affinity for kallidin and bradykinin and are instead constitutively expressed on 
most cell types including those in the airways (Leeb-Lundberg, 2005). Both bradykinin receptors 
are G protein-coupled receptors. Their stimulation, via the activation of Gαq/11 family of 
heterotrimeric G proteins, induces a number of intracellular events related to inflammation (Leeb-
Lundberg, 2005; Ricciardolo et al., 2000, 1998).  
 
3. Kinin metabolism 
Metabolic degradation of kinins is a major mechanism for the regulation of their actions and 
virtually all tissues and biological fluids contain enzymes that are capable of degrading these 
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peptides. Such enzymes include kininase I, also known as plasma carboxypeptidase N, and kininase 
II (Kaplan et al., 2002), the most important kinin-degrading enzymes in the endothelium of 
pulmonary vessels, which is identical to angiotensin-converting enzyme. Inhibition of this enzyme, 
with compounds such as captopril, results in a marked blockade of the metabolism of bradykinin. 
This enzyme has a higher affinity for bradykinin than for angiotensin I. Although the kininase II-
mediated metabolism may predominate in plasma and lungs, other enzymes such as aminopeptidase 
M and P, and neutral endopeptidase, also called enkephalinase, are involved in the inactivation of 
bradykinin as well (Kaplan et al., 2002).  
 
4. Role of bradykinin in airway inflammation 
The activation of the kinin-kallikrein system plays a fundamental role in sustaining an acute 
inflammatory response by means of the synthesis of kinins. Their action on tissues is associated 
with vasodilation (“rubor and calor”), increased vascular permeability (“tumor”), pain (“dolor”) and 
smooth muscle contraction (“function laesa”) which are defined as “cardinal signs” by Aulus 
Cornelius Celsus and therefore implicated in the pathogenesis of acute inflammation. During the 
onset and progression of inflammation the kinin-kallikrein system activation liberates bradykinin, 
whose half-life is very short (30 s) due to metabolism by kininases. However, this is long enough to 
trigger intracellular signalling, initiated via the activation of bradykinin B2 receptors (Colman, 
2006). Bradykinin, hence, initiates an acute inflammatory response and promotes the synthesis of 
other mediators, including prostaglandins, nitric oxide and tachykinins, modifying acute 
inflammatory response (Sainz et al., 2007) (Fig. 1). 
Kinins are well known as mediators of bronchial hyperresponsiveness in asthma (Roisman et al., 
1996). Different stimuli, including allergen exposure and viral infection are able to increase airway 
responsiveness associated with bradykinin, either in animal models (Ellis et al, 2004; Folkerts et al., 
2000; Ricciardolo et al., 1994b) or in human asthmatics (Ricciardolo et al., 2001; Ricciardolo et al., 
2012a).  
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In asthmatic airways, kinins are able to provoke inflammatory oedema, mucus production, cough 
and smooth muscle contraction (cardinal signs of acute asthma) through the direct activation of 
bradykinin B2 receptor, neural cholinergic pathway, capsaicin-sensitive type C sensory nerve fibres 
(effect referred as 'neurogenic inflammation') (Geppetti et al., 1995) and the release of various 
inflammatory mediators acting on endothelial, epithelial and smooth muscle cells.  
Some of these actions (direct activation of bradykinin B2 receptor on smooth muscle and 
stimulation of capsaicin-sensitive type C sensory fibres and vagal nerves) are excitatory by 
provoking acute bronchoconstriction (Geppetti et al., 1995; Ricciardolo et al., 1994b) while, on the 
other hand, others (activation of epithelial cells through release of PGE2 and nitric oxide produced 
by constitutive nitric oxide synthase) are protective in terms of reducing bronchoconstriction itself 
(Figini et al., 1996; Ricciardolo et al., 1994c, 1996).  
Another mechanism of action of bradykinin in the airways concerns its involvement in cough 
regulation. Inhaled bradykinin is able to induce cough: this effect is augmented by ACE inhibitors 
and seems to be dependent on capsaicin-sensitive non-myelinated bronchopulmonary C-fibers 
(Hewitt et al., 2016).  Furthermore, bradykinin is able to upregulate the TRPV1 receptor sensitivity 
on C fibres (Lee et al 2010) provoking the release of tachykinins (substance P and neurokinin A) 
(Geppetti et al., 1995) and, in addition, to induce the production of eicosanoids and prostaglandin in 
the airways (Lavorini et al., 2014; Hewitt et al., 2016) enhancing cough sensitivity (Lee et al 2010). 
Interestingly, a substantial increase of TRPV1-immunoreactive nerve profiles was found in the 
bronchial tissue of patients with chronic cough (Lee et al 2010).  
The expression of bradykinin B2 receptor is regulated by bradykinin itself as reported in in vitro 
studies on epithelial cells (Ricciardolo et al., 2012b) and lung/bronchial fibroblasts (Sabatini et al., 
2012, 2013). Bradykinin B2 receptor expression is constitutively enhanced in bronchial fibroblasts 
from asthmatics compared to normal bronchial fibroblasts (Sabatini et al., 2013) and bradykinin 
itself increases the expression of bradykinin B2 receptor, particularly in asthmatic bronchial 
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fibroblasts (Sabatini et al., 2013), showing a different cellular phenotype in relation to asthma (Th2-
driven) inflammatory milieu.  
Bradykinin-induced bradykinin B2 receptor expression in human lung fibroblasts is suppressed by 
corticosteroid treatment (budesonide) (Sabatini et al., 2012), suggesting a potential role for 
transcription factors in the modulation of bradykinin B2 receptor expression. Bradykinin B2 receptor 
expression is increased in the bronchial mucosa of mild allergic asthmatics after allergen compared 
to diluent challenge and, in addition, in bronchial fibroblasts from asthmatics after exposure to the 
Th2 cytokines IL-4 and IL-13 compared to the untreated fibroblasts (Ricciardolo et al., 2016). 
The nuclear factor–κB (NF-κB) p65 (Ser 276) inhibitor suppressed bradykinin B2 receptor up-
regulation induced by bradykinin and IL-4/IL-13 on bronchial fibroblasts in vitro, indicating that 
bradykinin B2 receptors protein expression is modulated by NF-κB pathway (Ricciardolo et al., 
2016). 
In human epithelial cells, the bradykinin B2 receptor mediates inflammatory signalling through 
activation of NF-κB and an increase in cyclooxygenase-2 expression (Chen et al., 2004). Moreover, 
the activation of MAPK/NF-κB and their related signal pathways stimulates the production of 
cytokines (Hayashi et al., 2000). Of interest, the release of neutrophil-related cytokines like IL-6 
and IL-8 could amplify the MAPK/NF-κB signalling inducing airway kinin receptor upregulation as 
well (Bryborn et al., 2004; Newton et al., 2002; Zhang et al., 2007a). Elevated levels of bradykinin 
(Christiansen et al., 1992), IL-8 and human tissue kallikrein activation are reported in 
bronchoalveolar lavage fluids from allergic subjects and asthmatic patients with rhinovirus infection 
(Christiansen et al., 2008), which underlines the relationship between bradykinin and IL-8 and their 
possible role in virus-induced asthma exacerbation.  
Less information is available on the role of  bradykinin B1 receptor in asthma. The bradykinin B1 
receptor antagonist R954 inhibited monocyte chemotactic protein-1 and interferon-gamma release, 
abolished TNF-α and IL-1β in bronchoalveolar lavage fluid in a mouse model of acute lung injury 
caused by lipopolysaccharide inhalation (Campanholle et al., 2010). Also an inhibitory effect of 
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blocking bradykinin B1 receptor was observed in terms of eosinophil activation, proliferation and 
migration in a murine model of asthma (Vasquez-Pinto et al., 2010). The presence of bradykinin B1 
and B2 receptors was confirmed on neutrophils and eosinophils from asthmatic and non-asthmatic 
subjects. A significantly greater protein expression of bradykinin B1 and B2 receptors was observed 
on eosinophils from asthmatic compared to non-asthmatic subjects (Bertram et al., 2007) (Bertram 
et al., 2009). A recent study showed the inhibitory effect of the bradykinin B1 receptor antagonist on 
BAL cell recruitment (eosinophils, neutrophils, macrophages and lymphocytes) after allergen 
challenge in a mouse model demonstrating the involvement of bradykinin B1 in the processes 
regulating inflammatory cell migration towards the airway lumen in asthmatic mice (Gurusamy et 
al., 2016). Administration of a bradykinin B2 receptor antagonist given before, during and 4 hours 
after antigen challenge significantly inhibited the late bronchial response, inflammatory mediators 
and the number of recruited neutrophils in an ovine model of asthma,  suggesting that bradykinin B2 
receptor selective antagonists may be potential drugs to reduce inflammatory cell infiltration in the 
late asthmatic response (Abraham et al., 2006). 
A new role for bradykinin in modifying the cellular inflammatory response in the airways has 
recently been depicted. Bradykinin stimulates the release of the neutrophilic chemotactic agent IL-
8, via both bradykinin B2 and B1 receptors stimulation, in epithelial bronchial cells (BEAS2B). 
Furthermore, in BEAS2B cells co-cultured with human neutrophils, bradykinin increased 
myeloperoxidase release and 3-nitrotyrosine production suggesting that bradykinin induces 
“nitrosative stress”, potentially mediated by IL-8 (Ricciardolo et al., 2012). “Nitrosative stress” is a 
pathogenic pathway involved in severe asthma (Fitzpatrick  et al. 2009; Ricciardolo et al. 2006) and 
on the basis of the results obtained in our in vitro study using epithelial cells co-cultured with 
neutrophils we may speculate that bradykinin-induced “nitrosative stress” might contribute to 
chronic airway inflammation in neutrophilic-dependent (non-type 2) asthma. 
Bradykinin is also a mediator of hereditary and ACE-Inhibitor-induced angioedema (Riha et al 
2017). Bradykinin-induced angioedema results from overproduction or reduced degradation of 
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bradykinin (Misra et al., 2016). This rise of bradykinin concentration causes an increase in vascular 
permeability, vasodilation and oedema formation (Hsu et al., 2012). Icatibant, a  bradykinin 
receptor competitive antagonist (Guo et al.,2017), has been tested in several clinical trials (Baş et 
al., 2015; Farkas et al., 2017; Sinert et al., 2017) reporting significant efficacy as a new therapeutic 
option in hereditary and ACE-Inhibitor-induced angioedema. 
 
5. Bradykinin in asthma 
Asthma is a chronic airway disease showing variable bronchial motor tone and airflow limitation 
(GINA Report 2017). Bronchial hyperresponsiveness, chronic inflammation and remodelling 
(structural alterations of airway wall) are major features of asthma and they are modulated, at least 
in part, by the epithelium layer (Ojiaku et al., 2017; Nair et al., 2017; Lambrecht and Hammad, 
2012; Ricciardolo et al., 2003; Davies, 2009).  
Different stimuli (allergen exposure, viral infection, cold air, various pollutants such as ozone and 
acidic molecules) may lead to acute airway inflammation, which triggers the production of pro-
inflammatory mediators like TNF-α, interleukins and, mostly, kinins (Christiansen et al., 1992; 
Folkerts et al., 2000; Yoshihara et al., 1996; Ricciardolo et al., 1999). These pro-inflammatory 
mediators can result in activation of intracellular signal pathways that induce upregulation of 
bradykinin receptors in the airways (Sabatini et al., 2013; Ricciardolo et al., 2016; Zhang et al., 
2007). In allergic mild asthma the expression of bradykinin B2 receptors is higher compared to 
control subjects (Ricciardolo et al., 2016). Subsequently, the kinin receptor upregulation and the 
epithelium dysfunction result in excessive bronchial hyperresponsiveness (Ricciardolo et al., 2001; 
Ricciardolo et al., 2003; Ricciardolo et al., 2016), which is a feature of uncontrolled asthma. Kinins 
are detected in bronchoaveolar lavage fluid from stable asthmatics (Christiansen et al., 1992). 
Furthermore, in atopic asthmatic patients, allergen exposure is associated with increased kinin 
concentrations in the epithelial lining fluid (Christiansen et al., 1992) and enhanced bronchial 
hyperresponsiveness to bradykinin (Ricciardolo et al., 2001), suggesting that anaphylactic response 
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is able to amplify kinin formation and to upregulate kinin receptors. Both bradykinin receptor 
subtypes seem to contribute to allergen-induced bronchial hyperresponsiveness in rats (Huang et al., 
1999). However, patients with asthma exhibit airway hyperresponsiveness to aerosolized bradykinin 
(bradykinin B2 receptor agonist), but not to des-Arg
9-bradyknin (bradykinin B1 receptor agonist) 
indicating that, in the human model, bradykinin B1 receptor is not involved in acute 
bronchoconstriction. In healthy humans inhalation of bradykinin has little or no effect, but in 
asthmatics it produces significant bronchoconstriction associated with the perception of cardinal 
asthma symptoms (“chest tightness, cough, wheezing and dyspnoea”) resembling a natural asthma 
attack (Abraham et al., 2006). 
Bradykinin is a weak constrictor in isolated human bronchi with epithelial integrity, while in vivo it 
is a potent bronchoconstrictor in asthmatic patients. This effect is due to the capability of bradykinin 
to activate cholinergic nerves (Reynolds et al., 1999), since bradykinin can stimulate airway 
parasympathetic ganglion neurons independently of sensory nerve activation, therefore providing an 
alternative mechanism for regulating airway parasympathetic tone (Kajekar and Myers, 2000). 
On the other hand, epithelium-derived bronchoprotective factors such as nitric oxide are released by 
bradykinin (Figini et al., 1996; Ricciardolo et al., 2000) negatively modulating enhanced bronchial 
hyperresponsiveness in mild asthma (Ricciardolo et al., 1996, 2001) (Fig. 1). A further study also 
showed the impairment of the bronchoprotective nitric oxide on the bradykinin-induced airway 
hyperresponsiveness in moderate-to-severe asthma suggesting the loss of this protective mechanism 
in difficult-to-control patients (Ricciardolo et al, 1997). In addition, clinical studies confirmed the 
role of corticosteroids in decreasing bronchial hyperresponsiveness to bradykinin and the 
bradykinin receptor expression in eosinophils/neutrophils from asthmatics in association with the 
improvement of respiratory symptoms (Bertram et al., 2007, 2009, Reynolds et al., 2002) indicating 
that the bradykinin-induced effects on the asthmatic airways seem to be corticosteroid sensitive.  
In line with the latter studies, dexamethasone, a well-known anti-inflammatory corticosteroid drug, 
inhibited the kinin receptor upregulation and bronchial hyperresponsiveness to kinins in murine 
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airways in vitro and the cigarette smoke-induced bronchial hyperresponsiveness in vivo (Zhang et 
al., 2004) (Lei et al., 2008) confirming a steroid sensitive modulation of kinin-induced airway 
responses. In a nice review, Zhang et al. pointed out that exposure to allergen, cigarette smoke or 
viral infection stimulated MAPK/NF-κB pathway promoting the gene upregulation of bradykinin 
receptors and subsequently increased bronchial responsiveness. These environmental risk factors 
result in the synthesis of pro-inflammatory mediators, such as TNF- and ILs, that activate 
intracellular MAPK and NF-κB (Zhang et al., 2013). 
Incubation of murine airway segments for 24 h in medium significantly increased bradykinin B1 
receptors and cyclooxygenase-2 expression which were significantly decreased by dexamethasone. 
(Xu and Cardell, 2014) Interestingly, incubation with nicotine significantly suppressed the 
cyclooxygenase-2 mediated and epithelium-dependent relaxations to bradykinin in organ culture 
(not reversed by dexamethasone) and, additionally, nicotine long-term exposure enhanced murine 
airway contractile responses to kinins suggesting that the nicotine-potentiating contractile effects in 
the airways might explain the mechanism of corticosteroid resistance in smoking asthma (Xu et al., 
2010; Xu and Cardell, 2014). 
Tabet et al. demonstrated a relationship between bradykinin-induced relaxation by means of 
hyperpolarization in human bronchi and the synthesis of the bronchorelaxing/hyperpolarizing 
factors epoxyeicosatrienoic acids produced by the endogenous CYP450 epoxygenase indicating a 
role for these arachidonic acid metabolites in hyperpolarization, via the large conductance Ca2+-
sensitive K+ channel, of airway smooth muscle cells induced by bradykinin (Tabet et al., 2013). 
Finally, we would like to point out that a main risk factor for asthma inception and/or worsening is 
chronic rhinitis (Brozek et al., 2017). Bradykinin- or allergen-induced nasal blockage and plasma 
extravasation are mediated by bradykinin B2 receptors in the human nasal airway (Shirasaki et al., 
2009; Thornton et al., 2013) and in animal models (Ricciardolo et al., 1994a;  Valenti et al., 2008). 
Moreover, in allergic rhinitis, the expression of bradykinin B1 receptor mRNA was significantly 
higher than in healthy subjects. Nasal allergen challenge increased bradykinin B1 receptor mRNA 
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expression in subjects with allergic rhinitis (Christiansen et al., 2002) indicating that both kinin 
receptors are involved in vascular responses of chronic rhinitis. 
 
6. B1 and B2 bradykinin receptor antagonists 
In normal human airways there is minimal expression of constitutive bradykinin B1 receptors in 
residential cells; this implies that the bronchoconstrictor response is mediated by bradykinin B2 
receptors (Abraham et al  2006; Ricciardolo et al., 2013). 
Activation of bradykinin B2 receptor is able to induce bronchoconstriction, vascular permeability, 
mucus secretion and cholinergic/sensory nerve stimulation. To counteract these effects several 
studies developed peptide and non-peptide receptor antagonists as potential therapeutic agents 
(Abraham et al  2006). 
The class of peptide B2 receptor antagonist is subdivided in three generation: the first is represented 
by NPC349 and later NPC567 and NPC17731: these are selective B2 receptor antagonist but with a 
reduced biological activity because of their susceptibility to enzymatic cleavage; the second 
generation of peptide antagonists is more potent and selective than the previous generation and it is 
resistant to peptidases: major representative is HOE 140 (Icatibant); the third generation is 
represented by B-9430, a longer acting peptide antagonist with a dual interaction with both 
receptors (Abraham et al  2006). 
Non-peptide antagonists were extensively studied: the first one WIN64338 had low affinity for 
human bradykinin B2 receptor, then FR173657 and FR184280 seem to be more effective and lastly 
MEN16132 that is a selective B2 receptor antagonist with good efficacy in inhibiting the 
bradykinin-induced bronchoconstriction in guinea pigs airways (Abraham et al  2006). 
Peptide antagonists, including Icatibant, were widely studied both in animal models and in humans 
showing a potential effect in blocking bradykinin-induced bronchocostrition (Leeb-Lundberg 2005). 
More than 20 years ago a double blinded, randomized, placebo-controlled phase II study has been 
performed in order to investigate the efficacy of the B2 bradykinin receptor antagonist Icatibant on 
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moderate to severe asthmatics (Akbary et al., 1996). Four weeks treatment of nebulized Icatibant 
(t.i.d. 900 p,g or 3000 mcg) led to a dose-dependent improvement in pulmonary function tests 
(PFTs) but no clinically relevant improvement in global symptom score was noted compared to 
placebo. During the study it has not been shown an acute bronchodilator effect but a gradually 
(week by week) increase of functional parameters until the end of active treatment suggesting a role 
as anti-inflammatory drug. No other trials with Icatibant have been performed and currently it 
would be interesting to test its effect in selected population of asthmatics on the basis of 
phenotypes. 
Non-peptide receptor antagonists, such as MEN16132 (Valenti et al 2008), seems to be more 
effective than peptide antagonists in cell cultures and in guinea pigs airways, but there are still too 
little data available on their efficacy in humans.  
Activation and upregulation of bradykinin B1 receptor in the airways of asthmatics is supported by 
the fact that its expression could be induced by several proinflammatory cytokines. Studies on B1 
receptor antagonists, R-715 (El-Kady et al., 2016) and BI113823 (Gurusamy et al., 2016), were 
conducted mainly on allergic airway inflammation. The former demonstrated a decrease in 
bronchial leukocyte infiltration, albumin, IL-1 β and serum OVA-specific IgE level and suppressed 
both bronchial cyclooxygenase-2 and inducible nitric oxide synthase expression (El-Kady et al., 
2016). The latter reduced inflammatory cell infiltration, cytokine production and reduced mucus 
expression (Gurusamy et al., 2016). Also these B1 receptor antagonists, as well as non-peptide B2 
receptor antagonists, were tested only in animal models. 
  
7. Bradykinin and matrix-related airway remodelling 
In asthma, the inflammatory milieu generates a state of abnormal activation of epithelial cells with 
release of growth factors, particularly TGF-β (Brightling et al., 2012; Ojiaku et al., 2017). 
Consequently, the latter stimulates mesenchymal cell proliferation and promotes differentiation of 
fibroblasts into myofibroblasts which express alpha-smooth muscle actin and secrete increased 
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amount of extracellular matrix components, such as type I collagen (Al-Muhsen et al., 2011; Ojiaku 
et al., 2017). This cascade, known as the “epithelial mesenchymal trophic unit”, probably drives the 
remodelling of the asthmatic airways (Davies et al., 2003). TGF-β increases intracellular calcium 
mobilization in human airway smooth muscle cells, therefore enhancing airway smooth muscle 
responsiveness to bradykinin (Kim et al., 2005). Moreover, TGF-β modulates the responsiveness to 
bradykinin by increasing mRNA and protein expression of bradykinin B2 receptor in human airway 
smooth muscle cells (Kim et al., 2005). In an in vitro model of embryonic kidney cells, bradykinin 
B2 receptor-mediated Gαq/11 activation was involved in cell proliferation via the mitogen-activated 
protein kinases (MAPK) activation, particularly p38 and extracellular-regulated kinase (ERK)1/2, 
and/or cross-talk with EGF-receptor (Zimmerman et al., 2011). Investigations of intracellular 
molecular signal mechanisms showed that activation of MAPK/NF-κB signal pathways regulates 
cellular events like differentiation, proliferation, apoptosis and production of pro-inflammatory 
mediators as well as expression of GPCR in airways (Damera et al., 2012; Gerthoffer and Singer, 
2003). In asthmatic patients, there are significant levels of phosphorylated ERK1/2 and p38 MAPK 
that correlate to the severity of airway disease ( Liu et al., 2008; Vallese et al., 2015). Bradykinin 
induced the differentiation of normal human lung fibroblasts into myofibroblasts (α-smooth muscle 
actin [α-SMA]+ cells) via bradykinin B2 receptor activation (Vancheri et al., 2005). We showed that 
bradykinin at low concentration (in the range of picomolar) induced cell proliferation in human 
bronchial fibroblasts from asthmatics and healthy controls, whereas at higher concentration (10-9-
10-6M) bradykinin induced myofibroblast differentiation and blocks proliferation (Sabatini et al., 
2013). In addition, the bradykinin-induced proliferation in asthmatic/normal fibroblast was 
dependent on metalloproteinase cleavage of the EGFR ligand precursors and EGFR transactivation, 
upon the bradykinin B2 receptor-ligand interaction, through activation of the G-protein cascade. The 
subsequent phosphorylation of ERK1/2 was involved in the regulation of cell proliferation in 
response (Sabatini et al., 2013) (Fig. 2). On the other hand, the p38-MAPK pathway mediated 
bradykinin-induced human bronchial fibroblast differentiation and polymerization of α-SMA+ fibres 
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(Sabatini et al., 2013). These experimental observations, showing that different concentrations of 
bradykinin trigger various cellular responses, suggest a temporal sequence of fibroblast driven 
airway remodelling, able to produce a progressive reduction in the airway lumen diameter in 
chronic asthma. Bradykinin triggered a concentration-dependent fibroblast gel contraction in 
conjunction with α-SMA overexpression, a phenomenon inhibited in α-SMA–siRNA-treated cells 
(Petecchia et al., 2010). In addition, bradykinin increased F-actin+ stress fibres polymerization and 
intracellular calcium levels, with phosphorylation of the myosin light-chain. All these data indicate 
that bradykinin-induced differentiation of fibroblasts into myofibroblasts and their contraction is 
mediated via bradykinin B2 receptor activation involving Ca
2+-calmodulin phosphorylation of the 
myosin light-chain dependent pathway (Petecchia et al., 2010) (Fig.2). 
 
8. Bradykinin and vascular airway remodelling 
Angiogenesis, a process of formation of new capillaries, from existing microvessels involves 
several steps beginning with localised degradation of the basement membrane of the existing 
vessels. Endothelial cells detach from the basement membrane and migrate into the perivascular 
space where they proliferate. The new endothelial cells then form tube-like structures that 
eventually join and form new capillaries. Different promoting or inhibiting factors regulate this 
process. VEGF stimulates endothelial cell migration and proliferation and is widely expressed in 
highly vascularised organs such as lungs. Angiogenin is implicated as a mitogen for vascular 
endothelial cells and induces vascular endothelial cell proliferation, migration and tubule formation. 
The kinin-kallikrein system is also involved in angiogenesis; in particular high molecular weight 
kininogens, the residue derived from high molecular weight kininogens hydrolysis to form 
bradykinin, is an angiogenesis inhibitor able to block endothelial cell proliferation and migration. 
Moreover, bradykinin promotes angiogenesis by upregulation of bFGF or VEGF, by regulation of 
vascular permeability, by stimulation of cell proliferation through bradykinin B2 receptor and by 
endothelial-nitric oxide synthase activation in endothelial cells (Colman, 2006). Angiogenesis is 
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recognised as a fundamental event in the development of airway remodelling that leads to 
irreversible obstruction (Postma and Timens, 2006). Proteins involved in angiogenesis, like VEGF 
and angiogenin are increased in asthma, and are associated with vascular remodelling (Hashimoto et 
al., 2005; Hoshino et al., 2001). We demonstrated that the VEGF-A+ cell counts in the bronchial 
mucosa (lamina propria) of old and young asthmatics were higher than in age matched non-
smoking controls, and that endothelial CD31+, angiogenin+, bradykinin B2 receptor
+ and bradykinin 
B1 receptor
+ cell numbers in the lamina propria were higher in old asthmatics than in age matched 
non-smoking controls, smoking controls and COPD patients (Ricciardolo et al., 2013). Furthermore, 
angiogenin+ cells were significantly increased in patients with severe asthma compared with 
patients with mild asthma, in conjunction with a higher number of CD4+ cells, neutrophils and 
eosinophils. All of these data suggest that angiogenin-related vascular remodelling is a feature of 
severe asthma and asthma in the elderly (Ricciardolo et al., 2013). In asthmatic patients, the number 
of bradykinin B2 receptor
+ cells is positively related to the number of bradykinin B1 receptor
+, 
angiogenin+ and CD31+ cells, indicating a functional interplay between the kinin system and 
neoangiogenesis in asthma (Ricciardolo et al., 2013). In addition, only the numbers of angiogenin+ 
cells were negatively related to forced expiratory volume 1s which confirms a role for angiogenin in 
developing progressive airflow limitation and fixed airway obstruction in chronic asthma. 
Interestingly, the number of neutrophils in the lamina propria of asthmatic bronchial biopsies was 
related to the number of CD31+ cells and B2 receptor
+ cells (Fig. 3) suggesting that neutrophilic 
asthma is associated with bradykinin B2 receptor expression and increased vascularization in 
asthmatic airways. 
Confocal microscopy showed that CD31+ cells (marker of endothelial cells) of capillary vessels in 
the lamina propria of asthmatic patients also co-express bradykinin B2 receptors, demonstrating a 
role for bradykinin B2 receptors in airway microvessel function (Ricciardolo et al., 2013). In 
addition, the large majority of cells in the lamina propria of asthmatics were fibroblasts (5B5+) co-
expressing bradykinin B2 receptors (72%), VEGF-A (87%) and angiogenin (80.5%). In an in vitro 
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study, bradykinin induces a significant increase of VEGF and angiogenin release in human 
asthmatic bronchial fibroblasts, and in particular angiogenin release was relatively higher in 
comparison with human bronchial fibroblast from COPD patients (Ricciardolo et al., 2013).  
These data infer the involvement of bradykinin receptors in modulating bronchial vascular 
remodelling in asthma, via fibroblasts activation and subsequent release of vascular growth factors 
(Fig. 1).  
 
9. Conclusion 
Kinins and their receptors are detected in the respiratory tract and could be highly produced and 
expressed under specific pathophysiological conditions in asthma. For a long time, bradykinin has 
been considered a mediator of acute responses in asthma (mainly as a mediator of neurogenic 
inflammation and airway responsiveness), but most recent evidence sheds light on additional long-
term effects of bradykinin in mesenchymal and endothelial cells activating downstream cascades 
(including release of growth factors and stimulation of MAPK/EGFR) involved in the chronicity 
and severity of asthma such as matrix- and vascular-related airway remodelling.  
Bradykinin and their receptors are highly involved in allergen-induced responses and it seems that 
bradykinin B2 receptor expression and bradykinin-related activities are specifically modulated by 
Th2 responses (due to IL-4/IL-13) in asthmatic fibroblasts pointing to a role in the remodelling 
process related to allergic severe asthma. On the other hand, also smoke- and virus-induced asthma 
showed up-regulation of bradykinin receptors. The latter seems to be associated with neutrophil-
dependent inflammatory process with a relative steroid resistance (“neutrophilic asthma”). 
Future studies are warranted in order to focus on the role of bradykinin and related receptors in 
specific asthma phenotypes (type 2 or non-type 2) (Wenzel et al., 2012) where the bradykinin 
pathway should be involved as molecular targets (personalized therapy). Actually, therapeutic 
strategies might be directed against the synthesis of kinins or the expression of bradykinin receptors 
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in order to modulate one of the most important clinically relevant features of asthma, namely airway 
remodelling. 
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Legend to the figures 
 
Fig. 1: Effects of bradykinin on asthmatic airways.  
In airway epithelial cells bradykinin stimulates the release of bronchorelaxing factors PGE2 and 
nitric oxide, the mucus secretion from human submucosal glands and the ion transport.  Bradykinin 
is a potent inducer of airway microvascular leakage and vascular permeability and causes prolonged 
leakage at all airway levels. Moreover it has direct effects on the recruitment and activation of 
inflammatory cells. Upon stimulation of bradykinin receptors, fibroblasts activation provokes the 
release of vascular growth factors (VEGF and angiogenin) able to modulate bronchial vascular 
remodelling in asthma. In airway smooth muscle bradykinin induces bronchoconstriction via direct 
stimulation of its receptors and via indirect neural activation (cholinergic nerves and C-fibre 
sensory nerves); nevertheless, epithelium-derived PGE2 and nitric oxide reduce excessive 
bronchoconstriction in asthma.  
 
Fig. 2: Bradykinin-induced intracellular pathways in human bronchial fibroblasts.  
Bradykinin B2 receptor coordinates human bronchial fibroblast proliferation and differentiation. 
These effects on bronchial fibroblast are due to activation of bradykinin B2 receptor and to 
subsequent stimulation of different MAPK/ERK pathways with the involvement of the 
metalloproteinase/EGF receptor signalling cascade.  
Low concentration of bradykinin is able to induce fibroblast proliferation via phosphorylation of 
p38 and ERK1/2. The latter is phosphorylated through metalloprotease-mediated cleavage of the 
EGF receptor ligand precursor. Higher concentration of bradykinin provokes the differentiation 
from fibroblast to myofibroblast via p38 pathway only. Myofibroblast differentiation is 
characterized by α-SMA polymerization in F-actin+ stress fibres and increased intracellular calcium 
levels in conjunction with phosphorylation of myosin light-chain. The organization in cytoskeletal 
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filaments of α-SMA and F-actin+ stress fibres reflects the plasticity of activated myofibroblasts 
promoting contractile behaviour. 
 
Fig. 3: Correlations between the number of neutrophils and CD31+ cells or bradykinin B2 
receptor+ cells  in the lamina propria of asthmatic bronchial biopsies. 
Panel A: correlation between number of neutrophils and CD31+  cells in the lamina propria of 
bronchial biopsies in asthmatics (cell/mm2) rs=0,47, P=0,02 
Panel B: correlation between number of neutrophils and B2 receptor
+ cells in the lamina propria of 
bronchial biopsies in asthmatics  (cell/mm2) rs=0,44, P=0,007 
These data are derived from: Ricciardolo et al. Expression of vascular remodelling markers in 
relation to bradykinin receptors in asthma and COPD. Thorax. 2013 Sep;68(9):803-11. 
doi:10.1136/thoraxjnl-2012-202741 (graphs unpublished). 
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